155 related articles for article (PubMed ID: 32570239)
1. Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics.
Lewis BJB; Branch DR
Pharmacology; 2020; 105(11-12):618-629. PubMed ID: 32570239
[TBL] [Abstract][Full Text] [Related]
2. The Dual Targeting of FcRn and FcγRs
Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
Front Immunol; 2021; 12():728322. PubMed ID: 34512662
[TBL] [Abstract][Full Text] [Related]
3. Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer.
Lewis BJB; Ville J; Blacquiere M; Cen S; Spirig R; Zuercher AW; Käsermann F; Branch DR
BMC Immunol; 2019 Dec; 20(1):44. PubMed ID: 31801459
[TBL] [Abstract][Full Text] [Related]
4. Next-generation Fc receptor-targeting biologics for autoimmune diseases.
Zuercher AW; Spirig R; Baz Morelli A; Rowe T; Käsermann F
Autoimmun Rev; 2019 Oct; 18(10):102366. PubMed ID: 31404703
[TBL] [Abstract][Full Text] [Related]
5. The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis.
Wu Y; Pan W; Hu X; Zhang A; Wei W
Biochem Pharmacol; 2021 Jan; 183():114360. PubMed ID: 33301760
[TBL] [Abstract][Full Text] [Related]
6. IVIG in autoimmune disease - Potential next generation biologics.
Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
[TBL] [Abstract][Full Text] [Related]
7. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
[TBL] [Abstract][Full Text] [Related]
8. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.
Anthony RM; Nimmerjahn F; Ashline DJ; Reinhold VN; Paulson JC; Ravetch JV
Science; 2008 Apr; 320(5874):373-6. PubMed ID: 18420934
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.
Prabagar MG; Choi HJ; Park JY; Loh S; Kang YS
Clin Exp Med; 2014 Nov; 14(4):361-73. PubMed ID: 23996469
[TBL] [Abstract][Full Text] [Related]
10. The antiinflammatory IgG.
Kaveri SV; Lacroix-Desmazes S; Bayry J
N Engl J Med; 2008 Jul; 359(3):307-9. PubMed ID: 18635437
[No Abstract] [Full Text] [Related]
11. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.
Patel DA; Puig-Canto A; Challa DK; Perez Montoyo H; Ober RJ; Ward ES
J Immunol; 2011 Jul; 187(2):1015-22. PubMed ID: 21690327
[TBL] [Abstract][Full Text] [Related]
12. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
[TBL] [Abstract][Full Text] [Related]
13. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.
Washburn N; Schwab I; Ortiz D; Bhatnagar N; Lansing JC; Medeiros A; Tyler S; Mekala D; Cochran E; Sarvaiya H; Garofalo K; Meccariello R; Meador JW; Rutitzky L; Schultes BC; Ling L; Avery W; Nimmerjahn F; Manning AM; Kaundinya GV; Bosques CJ
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1297-306. PubMed ID: 25733881
[TBL] [Abstract][Full Text] [Related]
14. Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.
Fitzpatrick EA; Wang J; Strome SE
Front Immunol; 2020; 11():496. PubMed ID: 32269572
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.
Nagelkerke SQ; Dekkers G; Kustiawan I; van de Bovenkamp FS; Geissler J; Plomp R; Wuhrer M; Vidarsson G; Rispens T; van den Berg TK; Kuijpers TW
Blood; 2014 Dec; 124(25):3709-18. PubMed ID: 25352126
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Neutrophil Function by Recombinant Human IgG1 Fc Hexamer in the Endogenous K/BxN Mouse Model of Rheumatoid Arthritis.
Almizraq RJ; Frias Boligan K; Lewis BJB; Cen S; Whetstone H; Spirig R; Käsermann F; Campbell IK; von Gunten S; Branch DR
Pharmacology; 2023; 108(2):176-187. PubMed ID: 36696888
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated Fc receptor function in active rheumatoid arthritis.
Magnusson SE; Wennerberg E; Matt P; Lindqvist U; Kleinau S
Immunol Lett; 2014 Nov; 162(1 Pt A):200-6. PubMed ID: 25194756
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb.
Magnusson SE; Andrén M; Nilsson KE; Sondermann P; Jacob U; Kleinau S
Clin Immunol; 2008 May; 127(2):225-33. PubMed ID: 18346938
[TBL] [Abstract][Full Text] [Related]
19. Targeting FcγRs to treat antibody-dependent autoimmunity.
Yu X; Lazarus AH
Autoimmun Rev; 2016 Jun; 15(6):510-2. PubMed ID: 26854400
[TBL] [Abstract][Full Text] [Related]
20. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases.
Norris PAA; Kaur G; Lazarus AH
Curr Opin Hematol; 2020 Nov; 27(6):392-398. PubMed ID: 32868670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
